Exscientia plc: Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
- Abstracts highlight pipeline programmes in precision oncology, including novel LSD1 inhibitor - Further detail on A2A programme, including novel biomarker for patient selection to be presented